Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ulipristal - HRA Pharma

Drug Profile

Ulipristal - HRA Pharma

Alternative Names: CDB-2914; ella; ellaOne; Esmya; Fibristal; HRP 2000; PGL-4001; RTI 3021-12; RU 44675; Ulipristal acetate; UPA; UPA C-IUS; UPA C-ring; UPA-IUS; UPA-UF; UPA-VR; VA-2914

Latest Information Update: 06 May 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HRA Pharma; National Institutes of Health (USA)
  • Developer AbbVie; ASKA Pharmaceutical; Gedeon Richter; HRA Pharma; Population Council (USA); PregLem
  • Class Antineoplastics; Norpregnadienes; Oral contraceptives; Small molecules
  • Mechanism of Action Selective progesterone receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Female genital diseases; Uterine leiomyoma

Highest Development Phases

  • Marketed Pregnancy; Uterine leiomyoma
  • Discontinued Breast cancer; Endometriosis; Menopausal syndrome

Most Recent Events

  • 02 May 2022 HRA Pharma has been acquired by Perrigo
  • 15 Jan 2021 The European Commission (EC) restricted the use of ulipristal acetate for the Uterine leiomyoma in the European Union followed by the CHMP opinion
  • 04 Sep 2020 EMA’s safety committee (PRAC) has recommended revocation of marketing authorisation of Ulipristal for the treatment of uterine leiomyoma
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top